respiratori
syndrom
coronaviru
merscov
identifi
potenti
threat
blood
safeti
studi
investig
efficaci
theraflex
uvplatelet
theraflex
mbplasma
pathogen
inactiv
system
inactiv
ebov
merscov
platelet
concentr
pc
plasma
respect
pc
plasma
spike
high
titer
cell
culturederiv
ebov
merscov
treat
variou
light
dose
ultraviolet
c
uvc
theraflex
uvplatelet
methylen
blue
mb
plu
visibl
light
mblight
theraflex
mbplasma
assess
residu
viral
infect
result
uvc
reduc
ebov
log
merscov
log
infect
pc
limit
detect
mblight
decreas
ebov
log
merscov
log
titer
plasma
nondetect
level
uvc
theraflex
mbplasma
mblight
effect
reduc
ebov
merscov
infect
platelet
plasma
respect
transmit
transfus
blood
product
howev
fact
mortal
rate
high
transmiss
mechan
still
complet
understood
highlight
need
increas
awar
potenti
threat
blood
safeti
merscov
merscov
envelop
positivesens
singlestrand
rna
coronaviru
interestingli
viral
rna
detect
sera
asymptomat
patient
outbreak
sever
acut
respiratori
syndrom
caus
anoth
coronaviru
sever
acut
respiratori
syndromecov
consequ
might
asymptomat
virem
phase
could
theoret
lead
transmiss
via
blood
transfus
howev
blood
transfus
implic
transmiss
merscov
date
ebov
member
filovirida
famili
envelop
pathogen
contain
negativesens
singlestrand
rna
genet
materi
ebov
diseas
extrem
fatal
known
caus
death
rate
recent
outbreak
ebov
diseas
west
africa
devast
guinea
liberia
sierra
leon
kill
nearli
person
affect
ebov
transmit
human
anim
spread
humantohuman
transmiss
via
direct
contact
infect
blood
andor
secret
differ
pathogen
inactiv
pi
techniqu
effect
inactiv
incapacit
viral
agent
render
unabl
replic
blood
compon
product
theraflex
uvplatelet
macopharma
novel
ultraviolet
c
uvc
base
pi
system
platelet
concentr
pc
current
undergo
clinic
efficaci
safeti
test
contrast
pi
technolog
work
without
exogen
ad
photoact
substanc
shortwav
uvc
light
nm
interact
nucleic
acid
directli
induc
format
cyclobutan
pyrimidin
pyrimidin
pyrimidon
dimer
prevent
elong
nucleic
acid
transcript
theraflex
mbplasma
macopharma
photodynam
pi
procedur
singl
unit
freshfrozen
plasma
system
base
administr
methylen
blue
mb
combin
visibl
light
mblight
develop
increas
viral
safeti
plasma
transfus
million
unit
treat
method
safe
transfus
patient
year
system
shown
effect
inactiv
broad
rang
differ
dna
rna
virus
includ
arbovirus
west
nile
viru
chikungunya
viru
zika
viru
recent
larg
outbreak
latter
virus
occur
outsid
previous
known
geograph
rang
serious
affect
thousand
peopl
studi
aim
investig
efficaci
theraflex
uvplatelet
theraflex
mbplasma
inactiv
merscov
ebov
pc
plasma
respect
compon
prepar
whole
blood
ml
collect
screen
unpaid
volunt
store
ml
cpd
accord
german
guidelin
blood
separ
red
blood
cell
rbc
plasma
buffi
coat
standard
blood
bank
procedur
plasma
unit
leukoreduc
filtrat
plasmaflex
macopharma
pool
split
store
use
plasmareduc
pc
prepar
pool
five
buffi
coat
describ
eriksson
colleagu
pool
mix
ml
pa
macopharma
equival
pase
suspens
centrifug
minut
g
pc
isol
leukoreduc
higheffici
filter
system
autostop
bc
haemonet
store
agit
platelet
plt
concentr
approxim
ml
plasma
content
approxim
residu
white
blood
cell
wbc
content
per
unit
air
routin
remov
plasma
unit
pc
antimerscov
enzymelink
immunosorb
assay
igg
euroimmun
use
screen
pc
plasma
unit
presenc
antibodi
merscov
product
test
antibodi
merscov
confirm
neg
use
inactiv
experi
plt
treat
use
theraflex
uvplatelet
pi
system
consist
uvc
illumin
devic
macotron
macopharma
dispos
set
ref
xuv
xu
macopharma
briefli
pc
irradi
uvc
light
wavelength
nm
total
dose
jcm
vigor
agit
ensur
uniform
treatment
compart
amount
uvc
energi
deliv
express
jcm
plasma
unit
mblighttreat
use
theraflex
mbplasma
macopharma
pi
system
consist
theraflex
mbplasma
kit
macotron
ledbas
illumin
devic
closedbag
system
contain
mb
pill
deliv
mg
mb
per
unit
plasma
approxim
mmoll
per
plasma
unit
standard
treatment
cycl
includ
initi
filtrat
leukoreduct
plasmaflex
filter
follow
second
postillumin
filtrat
step
remov
mb
photoproduct
blueflex
filter
plasma
process
pi
efficaci
test
deviat
standard
procedur
remov
mb
photoproduct
blueflex
filtrat
perform
exclus
determin
viru
inactiv
effect
illumin
amount
ledbas
light
energi
deliv
express
jcm
total
illumin
dose
set
jcm
routin
recommend
system
endpoint
titrat
assay
microtit
plate
employ
measur
viru
titer
eight
serial
dilut
per
parallel
sampl
vero
cell
use
indic
cell
sampl
titrat
perform
initi
dilut
vero
cell
exhibit
cytotox
plate
incub
humid
atmospher
co
day
incub
cell
layer
assess
virusinduc
chang
morpholog
cytopatholog
tissu
cultur
infecti
dose
tcid
calcul
accord
arber
method
express
log
tcid
effect
individu
process
step
viru
calcul
log
reduct
factor
rf
use
formula
rf
loga
loga
n
r
reduct
factor
total
viru
load
spike
n
total
viru
load
treat
sampl
overal
reduct
factor
express
sum
rf
step
limit
detect
assay
defin
lowest
tcid
achiev
noncytotox
sampl
concentr
vero
cell
atcc
togeth
zair
ebolaviru
strain
grown
approxim
confluenc
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
mmoll
lglutamin
mgml
streptomycin
iuml
penicillin
day
viral
supernat
collect
centrifug
aliquot
frozen
use
spike
experi
vero
cell
atcc
togeth
merscov
obtain
ron
fouchier
grown
approxim
confluenc
dmem
fb
mmoll
lglutamin
mgml
streptomycin
iuml
penicillin
day
viral
supernat
collect
centrifug
aliquot
frozen
use
spike
experi
viru
two
bag
pc
volum
ml
plasma
volum
ml
spike
viral
supernat
treat
describ
uvc
mblight
respect
treatment
deliv
increment
full
light
dose
jcm
uvc
jcm
mblight
differ
process
step
sampl
collect
viru
titrat
perform
refer
sampl
taken
bag
treatment
store
room
temperatur
test
end
experi
account
intrins
viru
inactiv
blood
product
viru
titer
spike
expect
dilut
factor
six
eight
blood
unit
use
one
pc
one
plasma
unit
use
ebov
inactiv
four
blood
unit
use
merscov
inactiv
viru
titer
pi
treatment
log
lower
expect
dilut
howev
addit
reduct
viru
titer
observ
cours
experi
result
infect
assay
demonstr
uvc
irradi
dosedepend
inactiv
ebov
merscov
plasmareduc
pc
tabl
jcm
full
uvc
dose
ebov
merscov
infect
level
detect
limit
result
viru
reduct
factor
greater
ebov
greater
merscov
tabl
light
dose
low
jcm
standard
full
light
dose
jcm
ledbas
illumin
inactiv
ebov
merscov
plasma
level
detect
limit
result
correspond
least
least
log
reduct
ebov
merscov
respect
theraflex
uvplatelet
theraflex
mbplasma
system
design
inactiv
remov
pathogen
plt
plasma
product
demonstr
wide
rang
pathogen
agent
mechan
theraflex
uvplatelet
shortwav
uvc
light
penetr
blood
fluid
cell
membran
caus
direct
coval
damag
nucleic
acid
pathogen
wbc
mechan
action
broadli
effect
extracellular
intracellular
transfusiontransmit
dnarnacontain
pathogen
virus
bacteria
protozoa
theraflex
mbplasma
combin
mba
phenothiazin
compound
intercal
viral
nucleic
acidwith
visibl
light
illumin
mbtreat
plasma
result
gener
singlet
oxygen
lead
destruct
viral
nucleic
acid
thu
prevent
viral
replic
mb
partial
penetr
cell
membran
mblight
treatment
less
effect
intracellular
virus
two
filter
integr
process
chain
although
second
filter
mainli
remov
mb
photoactiv
product
illumin
filter
multipl
layer
smallmesh
membran
capabl
remov
residu
wbc
rbc
plt
may
carri
intracellular
pathogen
recent
shown
two
filter
effici
remov
high
level
log
colonyform
unit
per
millilit
viabl
bacteria
bacteri
spore
assum
parasit
similar
size
also
remov
theraflex
mbplasma
procedur
previou
investig
show
filtrat
step
addit
mb
visibl
light
illumin
critic
achiev
complet
reproduc
elimin
trypanosoma
cruzi
caus
agent
chaga
diseas
estim
known
human
pathogen
consid
emerg
reemerg
abil
provid
proactiv
protect
emerg
infecti
agent
complementari
exist
blood
screen
program
major
addit
benefit
pi
system
blood
safeti
thu
imper
manufactur
continu
challeng
pi
system
new
infecti
agent
knowledg
first
studi
investig
efficaci
uvc
mblight
merscov
ebov
member
coronavirida
filovirida
famili
result
show
two
pi
system
reduc
merscov
ebov
titer
limit
detect
two
blood
unit
test
maximum
viral
titer
reduct
detect
cell
cultur
infect
assay
base
start
viral
concentr
blood
product
detect
limit
assay
turn
determin
suscept
cell
cultur
plasma
plt
suspens
previou
studi
observ
reduct
ebov
titer
merscov
titer
present
studi
beyond
expect
dilut
factor
pc
plasma
phenomenon
may
occur
due
presenc
nonspecif
immun
mediat
neutral
virus
plasma
mean
log
reduct
factor
least
merscov
least
ebov
pc
treat
uvc
least
merscov
least
ebov
plasma
treat
mblight
suggest
pi
technolog
use
studi
consider
effect
two
viru
type
studi
number
limit
exampl
number
replic
limit
safeti
constraint
experi
merscov
ebov
subject
highest
biosafeti
level
addit
largevolum
plate
could
perform
although
would
improv
detect
limit
enabl
exact
determin
log
reduct
factor
although
plasma
viral
rna
load
merscov
patient
may
log
genom
copiesml
median
viral
rna
load
log
genom
copiesml
detect
blood
ebola
patient
viru
titer
plasma
asymptomat
infect
convalesc
individu
recruit
donat
blood
may
significantli
lower
known
infecti
diseas
ebov
viral
titer
express
genom
copi
per
millilit
necessarili
reflect
infect
titer
viral
titer
measur
quantit
polymeras
chain
reaction
base
detect
small
fragment
viral
genom
infect
titer
describ
number
intact
function
viral
unit
requir
replic
diseas
transmiss
although
ebov
highli
infecti
low
dose
less
plaqueform
unit
viru
suffici
caus
diseas
abil
uvcand
mb
lightbas
system
reduc
merscov
ebov
infect
blood
product
sever
log
step
may
suffici
elimin
significantli
reduc
risk
transmiss
via
transfus
pc
plasma
conclus
studi
expand
list
pathogen
theraflex
uvplatelet
theraflex
mbplasma
effect
inactiv
pc
plasma
respect
